Shamburg News · 8-K filed Nov 5, 2026, 9:15 AM EST

MetaVia Reports Interim Phase 1 Part 3B Data for DA-1726 Showing Liver Fat and Weight Reductions

MTVA · MetaVia Inc.

  • Reg FD disclosure
  • Other event
  • Other
  • Materiality: medium

On November 5, 2026, MetaVia Inc. announced positive interim data from Part 3B of its Phase 1 trial of DA-1726, presented at the Precision Liver Symposium on November 4, 2026. The company reported a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted body weight reduction after 16 weeks of once-weekly DA-1726 treatment. The company also posted an updated corporate presentation and furnished the press release and presentation under Regulation FD and Item 8.01.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001104659-26-123110.

Written from the filing by Shamburg Markets. Figures are as reported by the company.